TITLE

Inhaled short acting ß agonist use in COPD and the risk of acute myocardial infarction

AUTHOR(S)
Suissa, S.; Assimes, T.; Ernst, P.
PUB. DATE
January 2003
SOURCE
Thorax;Jan2003, Vol. 58 Issue 1, p43
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Background: A recent study found that short acting β agonists used in the treatment of asthma and chronic obstructive pulmonary disease (COPD) may increase the risk of acute myocardial infarction. We investigated this hypothesis in patients with COPD already at high risk of cardiac disease. Methods: The Saskatchewan Health Services databases were used to form a population based cohort of all patients newly diagnosed with COPD over the age of 55 years identified between 1980 and 1997. All subjects were followed up until 1999, death, or the first occurrence of acute myocardial infarction. Those with a first acute myocardial infarction, fatal or non-fatal, were matched on calendar time and age with cohort members. Results: The cohort consisted of 12 090 subjects including 1127 cases with fatal or non-fatal acute myocardial infarction. The adjusted rate ratio for current use of inhaled β agonists was 1.12 (95% confidence interval (CI) 0.95 to 1.33), and for first time use it was 1.02 (95% CI 0.52 to 2.00). There was also no significant increase in risk when the analysis was restricted to subjects with cardiac risk factors such as hypertension and diabetes, or to subjects not having been prescribed β blocker medications. Conclusion: Short acting inhaled β agonist use among patients with COPD does not appear to increase the risk of fatal or non-fatal acute myocardial infarction.
ACCESSION #
16589526

 

Related Articles

  • Bronchial thermoplasty may improve asthma control up to 12 months after treatment. Ward, Neil // Thorax;Jun2007, Vol. 62 Issue 6, p556 

    The article discusses a study designed to assess the efficacy of bronchial thermoplasty up to 12 months after treatment. The patients had mild to severe asthma, were receiving treatment with inhaled corticosteroid and long-acting beta agonist inhalers. 56 of the 112 participants received...

  • Four in five asthma deaths may be due to long acting β agonists. Hagan, Pat // BMJ: British Medical Journal (International Edition);6/24/2006, Vol. 332 Issue 7556, p1467 

    The article discusses the results of a study which suggests that eighty per cent of asthma-related deaths in the United States may be due to long acting β agonists. Details of the study and its findings are provided. Long acting β agonists, such as salmeterol and formoterol, are examined.

  • Prescribing beta-agonists for respiratory disease. Scullion, Jane; Holmes, Steve // Independent Nurse;4/16/2010, p1 

    The article discusses about beta-agonists which are commonly prescribed to relieve symptoms of asthma & chronic obstructive pulmonary disease(COPD), focusing on the difference in its usage for both the diseases and the modes of action. After the initiation of inhaled corticosteroids(ICS), long...

  • Salbutamol eases COPD symptoms.  // Pulse;7/14/2003, Vol. 63 Issue 28, p13 

    Reports on the preference for beta agonists by patients with chronic obstructive pulmonary disease. Advantages of regular use of the drug.

  • COPD: Long-acting beta agonists canter survival benefit in older patients.  // Medical Economics;6/10/2011, Vol. 88 Issue 11, p65 

    The article focuses on the result of a study which confirms the survival advantage of long-acting beta agonists for treatment of chronic obstructive pulmonary diseases (COPD) in older patients.

  • Myocardial infarction following parenteral beta agonists for asthma in two patients with normal coronary arteries- a call for caution. Barilan, Ayelet; Aizikovich, Alex; Somin, Marina; Beilinson, Nick; Basevitch, Alon; Goland, Sorel; Malnick, Stephen // Internet Journal of Internal Medicine;2009, Vol. 8 Issue 1, p12 

    Background. Severe asthma is often treated with parenteral beta agonists. There is however, no solid evidence supporting this treatment and it is no longer recommended in current guidelines.Methods and Results. We have recently treated two patients who developed a myocardial infarction with...

  • Budesonide/formoterol may be used for adjustable maintenance dosing in asthma. Simcock, D. // Thorax;Jun2004, Vol. 59 Issue 6, p476 

    This randomized, double blind/open two phase multicentre study, sponsored by Astra Zeneca, was conducted over 7 months to find out if asthma control was better when patients adjusted the maintenance dose of inhaled budesonide/formoterol according to asthma symptoms than when fixed dose (FD)...

  • Developing robust formoterol-containing suspension pMDls with enhanced shelf lives. Slowey, Alex; Righton, Louise; Bainbridge, Paul // Pharmaceutical Technology Europe;Oct2009, Vol. 21 Issue 10, p54 

    The article focuses on the result of the study on the development of robust formoterol-containing pressurized metered-dose inhaler (pMDI) systems. It states that formoterol will be a characteristic of the asthma and chronic obstructive pulmonary disease (COPD) market, which is used together with...

  • ARCAPTA NEOHALER.  // Monthly Prescribing Reference;May2012, Vol. 28 Issue 5, pA-5 

    The article presents information on Arcapta Neohaler, the Indacaterol inhalation powder, from Novartis AG that is indicated for the treatment of patients with chronic obstructive pulmonary disease (COPD). It provides information that the drug belongs to Long-acting beta2-agonist (LABA), a...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sign out of this library

Other Topics